CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $57 | $0 | $31,016 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $56 | $215 | $211 | $199 |
| Gross Profit | $1 | -$215 | $30,805 | -$199 |
| % Margin | 1.8% | – | 99.3% | – |
| R&D Expenses | $22,693 | $19,962 | $19,537 | $18,551 |
| G&A Expenses | $19,806 | $12,245 | $11,578 | $8,324 |
| SG&A Expenses | $19,806 | $12,245 | $11,578 | $8,324 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$2 | $0 | $0 |
| Operating Expenses | $42,499 | $32,207 | $31,115 | $26,875 |
| Operating Income | -$42,498 | -$32,207 | -$99 | -$26,875 |
| % Margin | -74,557.9% | – | -0.3% | – |
| Other Income/Exp. Net | $596 | -$1,675 | -$709 | -$1,903 |
| Pre-Tax Income | -$41,902 | -$33,882 | -$808 | -$28,778 |
| Tax Expense | $0 | $0 | $0 | $6,306 |
| Net Income | -$41,902 | -$33,882 | -$808 | -$35,084 |
| % Margin | -73,512.3% | – | -2.6% | – |
| EPS | -0.37 | -0.32 | -0.008 | -0.36 |
| % Growth | -15.6% | -3,950.6% | 97.8% | – |
| EPS Diluted | -0.37 | -0.32 | -0.008 | -0.36 |
| Weighted Avg Shares Out | 113,323 | 105,718 | 102,150 | 97,971 |
| Weighted Avg Shares Out Dil | 113,323 | 105,718 | 102,150 | 97,971 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,680 | $3,170 | $2,627 | $2,013 |
| Interest Expense | $5,081 | $4,843 | $4,618 | $4,403 |
| Depreciation & Amortization | $56 | $215 | $211 | $2,699 |
| EBITDA | -$36,765 | -$38,510 | $4,021 | -$24,176 |
| % Margin | -64,500% | – | 13% | – |